Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease

Molecular Therapy

Volumn 15, Issue 1, 2007, Pages 62-68

  Gasmi, Mehdi ^a   Herzog, Christopher D ^a   Brandon, Eugene P ^a   Cunningham, Justine J ^a   Ramirez, G Anthony ^a   Ketchum, Elias T ^a   Bartus, Raymond T ^a  

^a Ceregene Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; NEUROTROPHIC FACTOR; NEURTURIN; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DATA ANALYSIS; DOPAMINERGIC NERVE CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE TRANSFER; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PARVOVIRUS VECTOR; RAT; STEADY STATE; VIRUS VECTOR;

ANIMALS; CELL LINE; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; DOPAMINE; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; GENOME, VIRAL; HUMANS; KINETICS; NERVE DEGENERATION; NEURTURIN; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33846011117     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300010     Document Type: Article

References (49)

1. Lang, AE and Lozano, AM (1998). Parkinson's disease. First of two parts. N Engl J Med 339: 1044-1053.
2. Lang, AE and Lozano, AM (1998). Parkinson's disease. Second of two parts. N Engl J Med 339: 1130-1143.
3. Kotzbauer, PT et al. (1996). Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature 384: 467-470.
4. Hurelbrink, CB and Barker, RA (2004). The potential of GDNF as a treatment for Parkinson's disease. Exp Neurol 185: 1-6.
5. Horger, BA et al. (1998). Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J Neurosci 18: 4929-4937.
6. Tseng, JL, Bruhn, SL, Zurn, AD and Aebischer, P (1998). Neurturin protects dopaminergic neurons following medial forebrain bundle axotomy. Neuroreport 9: 1817-1822.
7. Rosenblad, C, Kirik, D, Devaux, B, Moffat, B, Phillips, HS and Bjorklund, A (1999). Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. Eur J Neurosci 11: 1554-1566.
8. Hoane, MR, Gulwadi, AG, Morrison, S, Hovanesian, G, Lindner, MD and Tao, W (1999). Differential in vivo effects of neurturin and glial cell-line-derived neurotrophic factor. Exp Neurol 160: 235-243.
9. Oiwa, Y, Yoshimura, R, Nakai, K and Itakura, T (2002). Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease. Brain Res 947: 271-283.
10. Nutt, JG et al. (2003). Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60: 69-73.
11. Lang, AE et al. (2006). Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59: 459-466.
12. Love, S, Plaha, P, Patel, NK, Hotton, GR, Brooks, DJ and Gill, SS (2005). Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat Med 11: 703-704.
13. Patel, NK, Bunnage, M, Plaha, P, Svendsen, CN, Heywood, P and Gill, SS (2005). Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: A two-year outcome study. Ann Neurol 57: 298-302.
14. Gill, SS et al. (2003). Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9: 589-595.
15. Slevin, JT, Gerhardt, GA, Smith, CD, Gash, DM, Kryscio, R and Young, B (2005). Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg 102: 216-222.
16. McBride, JL and Kordower, JH (2002). Neuroprotection for Parkinson's disease using viral vector-mediated delivery of GDNF. Prog Brain Res 138: 421-432.
17. Treanor, JJ et al. (1996). Characterization of a multicomponent receptor for GDNF. Nature 382: 80-83.
18. Klein, RD et al. (1997). A GPI-linked protein that interacts with Ret to form a candidate neurturin receptor. Nature 387: 717-721.
19. Baloh, RH et al. (1997). TrnR2, a novel receptor that mediates neurturin and GDNF signaling through Ret. Neuron 18: 793-802.
20. Jing, S et al. (1997). GFRalpha-2 and GFRalpha-3 are two new receptors for ligands of the GDNF family. J Biol Chem 272: 33111-33117.
21. Creedon, DJ et al. (1997). Neurturin shares receptors and signal transduction pathways with glial cell line-derived neurotrophic factor in sympathetic neurons. Proc Natl Acad Sci USA 94: 7018-7023.
22. Widenfalk, J, Nosrat, C, Tomac, A, Westphal, H, Hoffer, B and Olson, L (1997). Neurturin and glial cell line-derived neurotrophic factor receptor-beta (GDNFR-beta), novel proteins related to GDNF and GDNFR-alpha with specific cellular patterns of expression suggesting roles in the developing and adult nervous system and in peripheral organs. J Neurosci 17: 8506-8519.
23. Golden, JP et al. (1998). Expression of neurturin, GDNF, and their receptors in the adult mouse CNS. J Comp Neurol 398: 139-150.
24. Burazin, TC and Gundlach, AL (1999). Localization of GDNF/neurturin receptor (c-ret, GFRalpha-1 and alpha-2) mRNAs in postnatal rat brain: differential regional and temporal expression in hippocampus, cortex and cerebellum. Brain Res Mol Brain Res 73: 151-171.
25. Cho, J, Kholodilov, NG and Burke, RE (2004). Patterns of developmental mRNA expression of neurturin and GFRalpha2 in the rat striatum and substantia nigra do not suggest a role in the regulation of natural cell death in dopamine neurons. Brain Res Dev Brain Res 148: 143-149.
26. Marks, WJJ et al. (2006). Phase I study of putaminal gene transfer with adeno-associated virus serotype 2 [AAV2]-Neurturin [NTN] (CERE-120) for Parkinson's disease: Preliminary observations. American Academy of Neurology. 58th annual Meeting. San Diego, CA.
27. Gash, DM, Zhang, Z, Ai, Y, Grondin, R, Coffey, R and Gerhardt, GA (2005). Trophic factor distribution predicts functional recovery in parkinsonian monkeys. Ann Neurol 58: 224-233.
28. Schnepp, BC, Clark, KR, Klemanski, DL, Pacak, CA and Johnson, PR (2003). Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J Virol 77: 3495-3504.
29. Hacein-Bey-Abina, S, et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419.
30. Bankiewicz, KS (2004). Long-term evaluation of AAV/AADC gene transfer in parkinsionian monkeys. American Academy of Neurology 56th Annual Meeting. San Francisco, CA.
31. During, MJ, Kaplitt, MG, Stern, MB and Eidelberg, D (2001). Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. Hum Gene Ther 12: 1589-1591.
32. Aminoff, M (2004). A Phase I open-label safety study of intrastriatal infusion of adeno-associated virus encoding human aromatic L-amino acid decarboxylase (AAV-hAADC-2) in subjects with advanced Parkinson's disease [AAV-hAADC-2-003]. OBA Protocol Number: 0307-593. http://www.gemcris.od.nih.gov/Contents/ GC_CLIN_TRIAL_RPT_VIEW.asp?WIN_TYPE=R&CTID=594.
33. Bennett, DA (2004). A phase I/II, dose-escalating, study to assess the safety and tolerability of CERE-110 [adeno-associated virus (AAV)-based, vector-mediated delivery of beta-nerve growth factor (β-NGF)] in subjects with mild to moderate Alzheimer's disease. OBA Protocol Number: 0401-623. http://www.gemcris.od.nih.gov/Contents/ GC_CLIN_TRIAL_RPT_VIEW.asp?WIN_TYPE=R&CTID=622.
34. Janson, C et al. (2002). Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum Gene Ther 13: 1391-1412.
35. Crystal, RG et al. (2004). Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis. Hum Gene Ther 15: 1131-1154.
36. Fjord-Larsen, L et al. (2005). Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct. Exp Neurol 195: 49-60.
37. Kaspar, BK, Erickson, D, Schaffer, D, Hinh, L, Gage, FH and Peterson, DA (2002). Targeted retrograde gene delivery for neuronal protection. Mol Ther 5: 50-56.
38. Brandon, EP et al. (2005). Controlled distribution of vector and neurturin following striatal administration of CERE-120, an AAV2-based vector being developed for Parkinson's disease. In: Society for Neuroscience 35th Annual Meeting. Washington, DC.
39. Bartus, RT et al. (2005). Biological activity of CERE-120, an AAV2 vector encoding human neurturin in the rat 6-hydroxydopamine model of nigrostriatal degeneration and in the young intact and aged rat. Society for Neuroscience 35th Annual Meeting. Washington, DC.
40. Herzog, CD. et al. (2004). Design of an AAV2 vector encoding chimeric cDNA to promote secretion of human neurturin and characretization of its anatomical and functinal effects using the 6-hydroxydopamine model of nigrostriatal degeneration. Society for Neuroscience, 34th Annual Meeting. Washington, DC.
41. Rosenblad, C, Martinez-Serrano, A and Bjorklund, A (1998). Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease. Neuroscience 82: 129-137.
42. Kirik, D, Rosenblad, C, Bjorklund, A and Mandel, RJ (2000). Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci 20: 4686-4700.
43. Georgievska, B, Kirik, D and Bjorklund, A (2002). Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer. Exp Neurol 177: 461-474.
44. Georgievska, B, Kirik, D, Rosenblad, C, Lundberg, C and Bjorklund, A (2002). Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. Neuroreport 13: 75-82.
45. Niwa, H, Yamamura, K and Miyazaki, J (1991). Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108: 193-199.
46. Ramirez, A. et al. (2004). Design and production of an AAV2 vector encoding a chimeric cDNA allowing efficient secretion of functional human neurturin from human cells. Mol Ther 9 (Suppl 1):S202-S203.
47. Xiao, X, Li, J and Samulski, RJ (1998). Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 72: 2224-2232.
48. West, MJ, Slomianka, L and Gundersen, HJ (1991). Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat Rec 231: 482-497.
49. Paxinos, G and Watson, C (2004). The Rat Brain in Stereotaxic Coordinates. Elsevier: New York, NY.